Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Detalles Bibliográficos
Autores principales: Dubois, Bruno, López‑Arrieta, Jesús, Lipschitz, Stanley, Doskas, Triantafyllos, Spiru, Luiza, Moroz, Svitlana, Venger, Olena, Vermersch, Patrick, Moussy, Alain, Mansfield, Colin D., Hermine, Olivier, Tsolaki, Magda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122276/
https://www.ncbi.nlm.nih.gov/pubmed/37087449
http://dx.doi.org/10.1186/s13195-023-01230-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122276/
https://www.ncbi.nlm.nih.gov/pubmed/37087449
http://dx.doi.org/10.1186/s13195-023-01230-9

Ejemplares similares